Michael Fuentes, MD
Pain Medicine · Corpus Christi, TXNPI 1689721383
Payments from drug & device makers
Across 29 payments — averaging $98.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$477
- Otsuka America Pharmaceutical, Inc.$294
- Amgen$280
- Teva Pharmaceuticals USA, Inc.$257
- Kyowa Kirin, Inc.$238
- AbbVie$227
- plus $1K from 10 others
What the payments were for
- Food & beverage$2,842100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $477 |
| Otsuka America Pharmaceutical, Inc. | 3 | $294 |
| Amgen | 3 | $280 |
| Teva Pharmaceuticals USA, Inc. | 3 | $257 |
| Kyowa Kirin, Inc. | 2 | $238 |
| AbbVie | 2 | $227 |
| Actelion Pharmaceuticals US, Inc. | 1 | $146 |
| Lilly USA, LLC | 1 | $125 |
| UCB, Inc. | 1 | $125 |
| Argenx US, Inc. | 1 | $122 |
| Acadia Pharmaceuticals Inc | 2 | $118 |
| Neurocrine Biosciences, Inc. | 1 | $111 |
| Melinta Therapeutics, LLC | 1 | $91 |
| Nevro Corp. | 1 | $90 |
| Gilead | 1 | $82 |
| Straumann USA LLC | 2 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,842 in reported general payments places this provider in the 45th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 13 | $11,445 |
| EliquisApixaban | 15 | $8,466 |
| Baclofen | 42 | $5,807 |
| Pregabalin | 12 | $5,176 |
| Hydrocodone-IbuprofenHydrocodone/Ibuprofen | 11 | $4,653 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 38 | $857 |
| Fentanyl | 12 | $707 |
| Oxycodone Hcl | 13 | $280 |
| Gabapentin | 29 | $240 |
| Tizanidine Hcl | 21 | $188 |
| Levothyroxine Sodium | 21 | $154 |
| Duloxetine Hcl | 14 | $143 |
| Tramadol Hcl | 19 | $122 |
| Losartan Potassium | 28 | $111 |
| Trazodone Hcl | 19 | $94 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Corpus Christi
- Puneet SayalCorpus Christi$153K
- Aaron CalodneyTyler$3M
- Mitchell EngleHouston$1.5M
- Melissa MurphyGrapevine$711K
- Shiraz YazdaniLubbock$632K
- Muhammad ZulqarnainDallas$556K
- Daniel PakHouston$460K
- Marvin ChangSugar Land$306K
- David LeimanHouston$281K
- Candice BurnetteSugar Land$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.